As another year draws to a close, what better way to recharge over the festive break than to dive into our 2022 paper round-up. Sticking to old habits, we’ve hand picked 15 of the CPG’s publications from the past year, with group authors past and present in bold.
Happy reading – and wishing you a Merry Christmas and a Happy (almost) New Year!
| Paper Title | Objective(s) | Journal & Authors | |
| 1. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study | The human papillomavirus (HPV) immunisation programme was introduced in England in September 2008. The authors sought to quantify the early effect of the English HPV immunisation programme on cervical cancer and cervical carcinoma in situ, namely as grade 3 cervical intraepithelial neoplasia registrations. | Lancet:
Milena Falcaro, Alejandra Castañon, Busani Ndlela, Marta Checchi, Kate Soldan, Jamie Lopez-Bernal, Lucy Elliss-Brookes, Peter Sasieni |
|
2. Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study |
The value of endoscopic surveillance for Barretts oesophagus (BE) remains debated. Using primary care records, secondary care records and cancer registry datasets, the authors examined the impact of a prior BE diagnosis, alongside accompanying clinical background and risk factors, on survival from oesophageal cancer and adenocarcinoma. | Cancer Medicine:
Judith Offman, Francesca Pesola, Rebecca C Fitzgerald, Willie Hamilton, Peter Sasieni |
|
3. Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study |
Several international cervical screening guidelines advise against high-risk human papillomavirus (HR-HPV) testing in women below age 30. The authors studied detection rates of cervical cancer and cervical intraepithelial neoplasia in women aged 24-29 screened with HR-HPV testing and with liquid-based cytology, compared with women screened at ages 30-49. | International Journal of Cancer:
Matejka Rebolj, Christopher S Mathews, Francesca Pesola, Alejandra Castanon, Henry Kitchener, HPV Pilot Steering Group |
|
4. Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial |
This study was nested within the BEST3 trial: a trial demonstrating the efficacy and safety of the Cytosponge-trefoil factor 3 test as a tool for detecting Barrett’s oesophagus (a precursor of oesophageal adenocarcinoma) in primary care. The authors sought to understand patient experiences of the BEST3 trial. | BMJ Open:
Roberta Maroni, Jessica Barnes, Judith Offman, Fiona Scheibl, Samuel G Smith, Irene Debiram-Beecham, Jo Waller, Peter Sasieni, Rebecca C Fitzgerald, Greg Rubin, BEST3 Consortium, Fiona M Walter
|
|
5. A case-control study to evaluate the impact of the breast screening programme on breast cancer incidence in England |
With existing uncertainty about overdiagnosis in mammography screening, this study aimed to estimate the effect of screening on breast cancer incidence and overdiagnosis in the NHS Breast Screening Programme in England, in women diagnosed at ages 47-89. |
Cancer Medicine:
Oleg Blyuss, Amanda Dibden, Nathalie J Massat, Dharmishta Parmar, Jack Cuzick, Stephen W Duffy, Peter Sasieni |
|
6. Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions |
The authors evaluated how COVID-19 temporary disruptions to primary cervical cancer screening services may differentially impact women, based on modelled disruption scenarios of 1-, 2-, or 5-year delay versus no delay, for both cytology-based and human papillomavirus (HPV)-based screening. |
medRxiv:
Emily A Burger, Inge M C M de Kok, James F O’Mahony, Matejka Rebolj, Erik E L Jansen, Daniel D de Bondt, James Killen, Sharon J Hanley, Alejandra Castanon, Jane J Kim, Karen Canfell, Megan A Smith, Mary Caroline Regan |
|
7. Non-speculum clinician-taken samples for human papillomavirus testing: a cross-sectional study in older women |
Speculum-based screening is effective in reducing cervical cancer incidence and mortality in women aged ≥65 years. However, speculum-based screening can become more uncomfortable after the menopause. This study examined test performance and acceptability of human papillomavirus testing on non-speculum, clinician-collected vaginal samples.
|
British Journal of General Practice:
Rebecca Landy, Tony Hollingworth, Jo Waller, Laura A Marlow, Jane Rigney, Thomas Round, Peter Sasieni, Anita W Lim
|
|
8. Self-sampling for cervical screening offered at the point of invitation: A cross-sectional study of preferences in England |
This study assessed preferences for human papillomavirus self-sampling if offered as an alternative to clinician-based screening at the point of invitation for cervical screening. | Journal of Medical Screening:
Hannah Drysdale, Laura A Marlow, Anita Lim, Peter Sasieni, Jo Waller |
|
9. The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials |
The authors aimed to understand and explain the existing variation in estimates of overdiagnosis within and across low-dose computed tomography lung cancer screening trials. | International Journal of Cancer:
Mengmeng Li, Li Zhang, Hadrien Charvat, Matthew E Callister, Peter Sasieni, Evangelia Christodoulou, Rudolf Kaaks, Mattias Johansson, Andre L Carvalho, Salvatore Vaccarella, Hilary A Robbins |
|
10. Impact of changes to the interscreening interval and faecal immunochemical test threshold in the national bowel cancer screening programme in England: results from the FIT pilot study |
With endoscopy capacity challenges from the COVID-19 pandemic, the NHS Bowel Cancer Screening Programme plans to lower the screening starting age. The authors analysed data from the English Faecal Immunochemical Testing (FIT) pilot study, to predict the detection of colorectal cancer, adenomas and advanced adenomas with increased interscreening interval and increased faecal haemoglobin threshold. |
British Journal of Cancer:
Shuping J Li, Tara Seedher, Linda D Sharples, Sally C Benton, Christopher Mathews, Rhian Gabe, Peter Sasieni, Stephen W Duffy |
|
11. Adherence to follow-up after the exit cervical cancer screening test at age 60-64: A nationwide register-based study |
In Denmark, human papillomavirus (HPV) testing has replaced cytology in primary cervical cancer screening for women aged 60-64. At this age, women are invited for an exit screening test. The authors investigated the adherence of 2,926 women aged 60-64 to the recommended follow-up after a non-negative (positive or inadequate) HPV test, alongside overall follow-up resource use. | Cancer Medicine:
Susanne F Jørgensen, Berit Andersen, Lone Kjeld Petersen, Matejka Rebolj, Sisse H Njor |
|
12. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care |
Men of African ancestry have demonstrated markedly higher rates of prostate cancer mortality than men of other races and ethnicities globally. The authors performed a collaborative review of relevant literature, to produce a conceptual model for evaluating racial inequities in prostate cancer care. | European Oncology:
Yaw A Nyame, Matthew R Cooperberg, Marcus G Cumberbatch, Scott E Eggener, Ruth Etzioni, Scarlett L Gomez, Christopher Haiman, Franklin Huang, Cheryl T Lee, Mark S Litwin, Georgios Lyratzopoulos, James L Mohler, Adam B Murphy, Curtis Pettaway, Isaac J Powell, Peter Sasieni, Edward M Schaeffer, Shahrokh F Shariat, John L Gore |
|
13. Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study |
The authors estimate the incidence and mortality rates for all cancers combined, and for 21 individual cancer types in Australia, up until 2044. They illustrate the potential effect of treatment delays due to the COVID-19 pandemic on future colorectal cancer mortality rates. | Lancet Public Health:
Qingwei Luo, Dianne L O’Connell, Xue Qin Yu, Clare Kahn, Michael Caruana, Francesca Pesola, Peter Sasieni, Paul B Grogan, Sanchia Aranda, Citadel J Cabasag, Isabelle Soerjomataram, Julia Steinberg, Karen Canfell |
|
14. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis |
The authors explored the efficacy of human papillomavirus (HPV) vaccination on the risk of HPV infection and recurrent diseases related to HPV infection, in individuals undergoing local surgical treatment. | BMJ:
Konstantinos S Kechagias, Ilkka Kalliala, Sarah J Bowden, Antonios Athanasiou, Maria Paraskevaidi, Evangelos Paraskevaidis, Joakim Dillner, Pekka Nieminen, Bjorn Strander, Peter Sasieni, Areti Angeliki Veroniki, Maria Kyrgiou |
|
15. Benefit of Biennial Fecal Occult Blood Screening on Colorectal Cancer in England: A Population-Based Case-Control Study |
The study evaluated the effect of participation in the national bowel cancer screening program on stage-specific colorectal incidence as a likely precursor of a mortality effect. | Journal of the National Cancer Institute:
Alejandra Castanon, Dharmishta Parmar, Nathalie J Massat, Peter Sasieni, Stephen W Duffy |
|